Compared with standard dual therapy, addition of aprepitant was generally well tolerated and provided consistently superior protection against CINV in patients receiving highly emetogenic cisplatin-based chemotherapy.

A first principle one‐dimensional (1‐D) dynamic model for tubular solid oxide fuel cell (SOFC) is developed. To convert the distributed model into a control relevant nonlinear state space model, an approximate analytical solution for reacting gas‐flow problem is proposed, and applied to the 1‐D SOFC dynamic model. Compared to numerical solutions, the proposed solution can significantly reduce requirements in computation, and thus, facilitate dynamic simulations and control applications. Distributed dynamic relations between current density and electromotive force (EMF) are investigated. Diffusion, inherent impedance, primary flow, heat transfer, and internal reforming/shifting reaction are considered simultaneously. Dynamic responses of the interested variables when external current, fuel and air inlet streams are perturbed by step changes are investigated through simulations. © 2008 American Institute of Chemical Engineers AIChE J, 2008.

The aprepitant regimen provided superior efficacy in the treatment of CINV in a broad range of patients receiving MEC (non-AC or AC) in both no vomiting and complete response endpoints. Aprepitant was generally well tolerated. These results show the benefit of including aprepitant as part of the standard antiemetic regimen for cancer patients receiving MEC.

Given with ondansetron and dexamethasone, single-dose intravenous fosaprepitant (150 mg) was noninferior to standard 3-day oral aprepitant in preventing CINV during OP and DP.

The neurokinin-1-receptor antagonist L-754,030 prevents delayed emesis after treatment with cisplatin. Moreover, combining L-754,030 with granisetron plus dexamethasone improves the prevention of acute emesis.